Literature DB >> 18751215

Anti-vascular therapy: a new approach to cancer treatment.

A J Hayes1, L Y Li, M E Lippman.   

Abstract

Entities:  

Year:  2000        PMID： 18751215      PMCID： PMC1070721          DOI： 10.1136/ewjm.172.1.39

Source DB:  PubMed          Journal:  West J Med        ISSN： 0093-0415


× No keyword cloud information.
  30 in total

Review 1.  Sequestration and release of basic fibroblast growth factor.

Authors:  I Vlodavsky; P Bashkin; R Ishai-Michaeli; T Chajek-Shaul; R Bar-Shavit; A Haimovitz-Friedman; M Klagsbrun; Z Fuks
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

2.  Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.

Authors:  M Relf; S LeJeune; P A Scott; S Fox; K Smith; R Leek; A Moghaddam; R Whitehouse; R Bicknell; A L Harris
Journal:  Cancer Res       Date:  1997-03-01       Impact factor: 12.701

3.  Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470.

Authors:  A P Kudelka; C F Verschraegen; E Loyer
Journal:  N Engl J Med       Date:  1998-04-02       Impact factor: 91.245

Review 4.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

5.  Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation.

Authors:  L A Liotta; J Kleinerman; G M Saidel
Journal:  Cancer Res       Date:  1974-05       Impact factor: 12.701

6.  A secreted FGF-binding protein can serve as the angiogenic switch in human cancer.

Authors:  F Czubayko; E D Liaudet-Coopman; A Aigner; A T Tuveson; G J Berchem; A Wellstein
Journal:  Nat Med       Date:  1997-10       Impact factor: 53.440

7.  Angiostatin induces and sustains dormancy of human primary tumors in mice.

Authors:  M S O'Reilly; L Holmgren; C Chen; J Folkman
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

8.  Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers.

Authors:  M Nguyen; H Watanabe; A E Budson; J P Richie; D F Hayes; J Folkman
Journal:  J Natl Cancer Inst       Date:  1994-03-02       Impact factor: 13.506

9.  A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines.

Authors:  D R Senger; C A Perruzzi; J Feder; H F Dvorak
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

10.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.

Authors:  K M Dameron; O V Volpert; M A Tainsky; N Bouck
Journal:  Science       Date:  1994-09-09       Impact factor: 47.728
View more
  6 in total

1.  Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.

Authors:  Niranjan Awasthi; Changhua Zhang; Anna M Schwarz; Stefan Hinz; Margaret A Schwarz; Roderich E Schwarz
Journal:  Mol Cancer Ther       Date:  2014-03-07       Impact factor: 6.261

2.  Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.

Authors:  Niranjan Awasthi; Stefan Hinz; Rolf A Brekken; Margaret A Schwarz; Roderich E Schwarz
Journal:  Cancer Lett       Date:  2014-12-16       Impact factor: 8.679

3.  Dietary restriction promotes vessel maturation in a mouse astrocytoma.

Authors:  Ivan Urits; Purna Mukherjee; Joshua Meidenbauer; Thomas N Seyfried
Journal:  J Oncol       Date:  2011-12-27       Impact factor: 4.375

4.  Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.

Authors:  Niranjan Awasthi; Changhua Zhang; Winston Ruan; Margaret A Schwarz; Roderich E Schwarz
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

5.  Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.

Authors:  Niranjan Awasthi; Changhua Zhang; Stefan Hinz; Margaret A Schwarz; Roderich E Schwarz
Journal:  J Exp Clin Cancer Res       Date:  2013-03-06

6.  The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer.

Authors:  Neus Martínez-Bosch; Pedro Enrique Guerrero; Mireia Moreno; Anabel José; Mar Iglesias; Jessica Munné-Collado; Héctor Anta; Joan Gibert; Carlos Alberto Orozco; Judith Vinaixa; Cristina Fillat; Francesc Viñals; Pilar Navarro
Journal:  Oncotarget       Date:  2016-07-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.